Research Article Details
| Article ID: | A21899 |
| PMID: | 24974489 |
| Source: | J Assoc Physicians India |
| Title: | Hepatocyte growth factor, adiponectin and hepatic histopathology in non-alcoholic steatohepatitis. |
| Abstract: | OBJECTIVES: Hepatocyte growth factor (HGF) and Adiponectin are adipokines. Serum HGF and adiponectin levels are strongly associated with liver disease, obesity, insulin resistance and metabolic syndrome (MS). Non alcoholic steatohepatitis (NASH) is the hepatic component of metabolic syndrome. Our aim was to elucidate the status of HGF, adiponectin levels and histopathology of liver in NASH. METHODS: This study was conducted among 50 subjects (25 patients and 25 controls) age and sex matched attending OPD. Patients were randomly selected for the study and after explaining in detail design of the study, written consent was taken. Institutional ethical approval was also taken.The only diagnostic method for NASH is liver biopsy (after exclusion of other causes based upon clinical examination and laboratory investigations) and pathological grading and staging was done according to Brunt classification. Diagnosis of patients was done on the basis of liver biopsy and fasting HGF and adiponectin were performed with commercially available ELISA kits (quantikine HGF and adiponectin ELISA kits). RESULTS: Mean serum HGF in patient and control groups were 2.33 +/- 0.66 pg/ml and 0.56 +/- 0.21 pg/ml respectively (p < 0.001). Mean serum adiponectin in patient and control groups were 6.93 +/- 1.50 ng/ml and 14.54 +/- 3.58 ng/ml respectively (p < 0.001). Multiple regression analysis revealed that statistically significant difference was found (p < .001) when comparing mean brunt grade and brunt stage (hepatic histopathology) with fasting serum adiponectin and HGF CONCLUSION: Fasting serum HGF was significantly high and fasting serum adiponectin was significantly low in patients of various grades of hepatic histopathology in NASH.Various parameters of MS were significantly correlated with various stages of hepatic histopathology, as well as decreased serum adiponectin and increased fasting serum HGF. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |